MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. Gene Biodesign has been certified to process customer samples in their laboratory in northern Taipei county for NimbleGen array applications including Comparative Genomic Hybridization (CGH), Chromatin Immunoprecipitation-on-chip (ChIP-chip), DNA Methylation and Gene Expression. Gene Biodesign passed rigorous certification standards using the Roche NimbleGen workflow, which includes the 2 micron NimbleGen MS 200 Microarray Scanner. Gene Biodesign will provide NimbleGen array services at their location in the Mackay Memorial Hospital, a teaching hospital responsible for the clinical training of interns in modern medical studies and clinical care. The collaborative atmosphere between clinicians and genomics researchers will provide a broad perspective on their studies.
“As the latest Roche NimbleGen CSP, Gene Biodesign has made a significant investment in cutting-edge genetic analysis technologies and will provide support for these technologies in Asia,” said Jessica Chen, CEO of Gene Biodesign. “We feel we offer a superb value proposition in that we can provide certified services to academic and clinical research segments alike. We hope this collaborative effort will result in a new era of genomic studies for the life sciences and human public health.”
Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc., added, “Roche NimbleGen is extremely excited to welcome Gene Biodesign to our family of certified service providers in Asia, where they will support the entire portfolio of NimbleGen array applications. We are confident that adding Gene Biodesign to the program will be a major factor in achieving high growth for Roche NimbleGen in Taiwan, as well as throughout Asia.”
For more information about Roche NimbleGen, please visit www.nimblegen.com
Headquartered in Basel, Switzerland, Roche (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
About Gene Biodesign Enterprises Co.
Gene Biodesign is not only a leading services provider in the microarray technology, but also a professional provider in scientific equipment. Gene Biodesign is an important distributor of analytical instrumentation in Taiwan and offers a wide range of products for genomics, proteomics and bioinformatics. With our core value of “quality” our team of professional and enthusiastic employees at Gene Biodesign is eager to provide customers with the highest quality services and products. Our mission is to help our customers find opportunities for research and advanced study in life sciences and human public health.
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN is a trademark of Roche.
Other brands or product names are trademarks of their respective holders.
KEYWORDS: United States Europe Asia Pacific North America Switzerland Taiwan Wisconsin
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Genetics Hospitals Medical Devices Pharmaceutical Research Science